Technical Analysis for ESPR - Esperion Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Down |
| Historical ESPR trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Doji - Bullish? | Reversal | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Down 3 Days in a Row | Weakness | 0.00% | |
| Oversold Stochastic | Weakness | 0.00% | |
| NR7 | Range Contraction | -0.11% | |
| Wide Bands | Range Expansion | -0.11% | |
| Oversold Stochastic | Weakness | -0.11% | |
| 180 Bearish Setup | Bearish Swing Setup | -1.08% | |
| Wide Bands | Range Expansion | -1.08% | |
| Oversold Stochastic | Weakness | -1.08% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| 60 Minute Opening Range Breakdown | about 7 hours ago | |
| Up 1% | about 9 hours ago | |
| 60 Minute Opening Range Breakout | about 10 hours ago | |
| Down 3% | about 10 hours ago | |
| Down 2 % | about 11 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 02/25/2021
Esperion Therapeutics, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of therapies for the treatment of patients with low-density lipoprotein cholesterol and other cardiometabolic risk factors. Its products include ETC-1002, an oral molecule therapy that is in Phase IIa clinical trials to treat lipid and carbohydrate metabolic pathways; ESP41091, which is in pre-clinical trials for type 2 diabetes and obesity treatment; and 4WF, a synthetic therapy that is in pre-clinical trials to reverse the deleterious effects of atherosclerosis. The company is based in Plymouth, Michigan.
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diabetes Lipid Obesity Cardiology Cholesterol Lipoprotein Lipids Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Niacin Atherosclerosis Lipoproteins
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Diabetes Lipid Obesity Cardiology Cholesterol Lipoprotein Lipids Gabaa Receptor Positive Allosteric Modulators Low Density Lipoprotein Niacin Atherosclerosis Lipoproteins
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 53.73 |
| 52 Week Low | 23.9 |
| Average Volume | 860,764 |
| 200-Day Moving Average | 35.18 |
| 50-Day Moving Average | 29.48 |
| 20-Day Moving Average | 30.00 |
| 10-Day Moving Average | 28.09 |
| Average True Range | 2.06 |
| ADX | 17.67 |
| +DI | 20.23 |
| -DI | 22.75 |
| Chandelier Exit (Long, 3 ATRs ) | 30.71 |
| Chandelier Exit (Short, 3 ATRs ) | 32.37 |
| Upper Bollinger Band | 35.24 |
| Lower Bollinger Band | 24.77 |
| Percent B (%b) | 0.26 |
| BandWidth | 34.87 |
| MACD Line | -0.80 |
| MACD Signal Line | -0.47 |
| MACD Histogram | -0.3359 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 30.12 | ||||
| Resistance 3 (R3) | 29.98 | 28.97 | 29.67 | ||
| Resistance 2 (R2) | 28.97 | 28.29 | 29.03 | 29.52 | |
| Resistance 1 (R1) | 28.21 | 27.87 | 27.71 | 28.35 | 29.38 |
| Pivot Point | 27.20 | 27.20 | 26.94 | 27.26 | 27.20 |
| Support 1 (S1) | 26.44 | 26.52 | 25.94 | 26.58 | 25.54 |
| Support 2 (S2) | 25.43 | 26.10 | 25.49 | 25.40 | |
| Support 3 (S3) | 24.67 | 25.43 | 25.25 | ||
| Support 4 (S4) | 24.81 |
